Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Spire Healthcare (LSE:SPI) publishes scheme document for Tulip consortium bid; votes on 30 October

Spire Healthcare Group plc (LSE:SPI) published the scheme document on 29 September 2026. It covers the acquisition by Tulip UK Bidco Limited, which acts for funds managed or advised by Toscafund Asset Management LLP, THCP Advisory Limited and Ares Management Limited. The deal is …

Ankur Sharma | 30 September 2026

Why Is Proteome Sciences [LSE:PRM] in Focus After a 3.93% Rise?

•The company remains focused on proteomics services, protein biomarkers, mass spectrometry and chemoproteomics.

Ankur Sharma | 30 September 2026

Why Is NIOX Group [LSE:NIOX] in Focus After a 3.66% Rise?

•H1 2026Revenuewas £24.0 million, with Clinical revenue up 3% to £20.6 million.

Ankur Sharma | 30 September 2026

Vulcan Two Group (LSE:VUL) reports £10.0m revenue in first results and renames as Molecule Group

Vulcan Two Group plc (LSE:VUL) released interim results for the six months to 30 June 2026 alongside confirmation of a change of name. The company will become Molecule Group plc, trading under the ticker MOL, with the change expected "in the coming days". A …

Ankur Sharma | 30 September 2026

Why Did ProBiotix Health Fall 8.51% as Investors Focused on Commercial Growth? (LSE:PBX)

ProBiotix Health plc (LSE:PBX) operates in the health and nutrition technology space, with a focus on microbiome-based products and ingredients. Its commercial proposition depends on translating scientific research into consumer and partner products. That makes licensing, distribution, customer adoption andRecurring Revenueimportant drivers of market …

Ankur Sharma | 30 September 2026

Why Did Genus (LSE:GNS) Gain 2.53% as Animal Genetics Innovation Remains in Focus?

Genus gained 2.53% on 29 September after recent full-year results and continued progress in animal genetics and gene-editing technologies kept the company in focus. TheBusinessis positioned at the intersection of livestock productivity, food security and biotechnology.

Ankur Sharma | 30 September 2026

Incanthera (LSE:INC) closes £355,000 loan note financing after year-end cash of just £4,000

Incanthera plc (LSE:INC) made two announcements on 29 September 2026. The first was its final results for the year to 31 March 2026. The second confirmed completion of a £355,000 financing through convertible loan notes (CLNs).

Ankur Sharma | 30 September 2026

Genflow Biosciences (LSE:GENF) cuts costs and holds £0.63m cash ahead of canine trial readout

Genflow Biosciences Plc (LSE:GENF), which develops SIRT6 gene therapies for age-related diseases, published unaudited half-year results for the six months to 30 June 2026. All of its human health programmes also moved onto a messenger RNA-lipid nanoparticle (mRNA-LNP) delivery platform.

Ankur Sharma | 30 September 2026

Why Is MicroSalt [LSE:SALT] in Focus After a 3.57% Rise?

•H1 2026Revenuereached a record US$1.4 million, up 67% year on year.

Ankur Sharma | 30 September 2026

AstraZeneca (LSE:AZN) takes about 12% of Summit Therapeutics in $2bn share investment and ivonescimab trial pact

In an announcement on 29 September 2026, AstraZeneca set out two linked agreements with Summit Therapeutics Inc. The first is a $2bn strategicInvestmentin newly issued Summit stock. The second is a clinical collaboration to test Sone-Ve with ivonescimab in gastrointestinal cancers.

Ankur Sharma | 30 September 2026
Support

Hi! How can we help you today?

Loading…